AU2012342355B2 - Scalable lentiviral vector production system compatible with industrial pharmaceutical applications - Google Patents

Scalable lentiviral vector production system compatible with industrial pharmaceutical applications Download PDF

Info

Publication number
AU2012342355B2
AU2012342355B2 AU2012342355A AU2012342355A AU2012342355B2 AU 2012342355 B2 AU2012342355 B2 AU 2012342355B2 AU 2012342355 A AU2012342355 A AU 2012342355A AU 2012342355 A AU2012342355 A AU 2012342355A AU 2012342355 B2 AU2012342355 B2 AU 2012342355B2
Authority
AU
Australia
Prior art keywords
cells
transfection
plasmid
culture
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012342355A
Other languages
English (en)
Other versions
AU2012342355A1 (en
Inventor
Mehdi Gasmi
Nicolas Marceau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genethon
Original Assignee
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48469165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012342355(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genethon filed Critical Genethon
Publication of AU2012342355A1 publication Critical patent/AU2012342355A1/en
Application granted granted Critical
Publication of AU2012342355B2 publication Critical patent/AU2012342355B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012342355A 2011-11-24 2012-11-26 Scalable lentiviral vector production system compatible with industrial pharmaceutical applications Ceased AU2012342355B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161563566P 2011-11-24 2011-11-24
EP11306551 2011-11-24
US61/563,566 2011-11-24
EP11306551.0 2011-11-24
PCT/EP2012/073645 WO2013076309A1 (en) 2011-11-24 2012-11-26 Scalable lentiviral vector production system compatible with industrial pharmaceutical applications

Publications (2)

Publication Number Publication Date
AU2012342355A1 AU2012342355A1 (en) 2014-07-17
AU2012342355B2 true AU2012342355B2 (en) 2017-10-12

Family

ID=48469165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012342355A Ceased AU2012342355B2 (en) 2011-11-24 2012-11-26 Scalable lentiviral vector production system compatible with industrial pharmaceutical applications

Country Status (20)

Country Link
US (3) US20140315294A1 (en22)
EP (2) EP2782997B1 (en22)
JP (2) JP6280869B2 (en22)
CN (2) CN109097398A (en22)
AU (1) AU2012342355B2 (en22)
BR (1) BR112014012600A2 (en22)
CA (1) CA2856455C (en22)
CY (1) CY1120103T1 (en22)
DK (1) DK2782997T3 (en22)
ES (1) ES2663815T3 (en22)
HR (1) HRP20180424T1 (en22)
HU (1) HUE036742T2 (en22)
LT (1) LT2782997T (en22)
PL (1) PL2782997T3 (en22)
PT (1) PT2782997T (en22)
RS (1) RS57066B1 (en22)
SG (1) SG11201402584RA (en22)
SI (1) SI2782997T1 (en22)
SM (1) SMT201800174T1 (en22)
WO (1) WO2013076309A1 (en22)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782997B1 (en) 2011-11-24 2018-01-10 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
FR3010720B1 (fr) * 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
WO2015097650A1 (en) * 2013-12-23 2015-07-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
EP4316500A3 (en) 2015-05-13 2024-04-10 CSL Behring Gene Therapy, Inc. Bio-production of lentiviral vectors
CN105483092A (zh) * 2015-10-10 2016-04-13 和元生物技术（上海）股份有限公司 一种中试化生产重组腺相关病毒的新技术
SG11201806976UA (en) 2016-02-23 2018-09-27 Immune Design Corp Multigenome retroviral vector preparations and methods and systems for producing and using same
CN109071594A (zh) * 2016-04-14 2018-12-21 崔泽尔有限公司 具有恒流泵/管道系统的固定床生物反应器
CN116144500A (zh) 2016-04-14 2023-05-23 崔泽尔有限公司 具有恒流泵/管道系统的固定床生物反应器
WO2018064584A1 (en) * 2016-09-30 2018-04-05 Life Technologies Corporation Serum-free suspension system for lentiviral production
CN106867877A (zh) * 2017-02-15 2017-06-20 昆明医科大学第二附属医院 一种密闭式慢病毒载体培养装置和培养方法
US11674115B2 (en) 2017-10-31 2023-06-13 Global Life Sciences Solutions Usa Llc Flexible bag
CN111727251B (zh) 2017-11-21 2024-09-20 克里斯珀医疗股份公司 用于治疗常染色体显性色素性视网膜炎的材料和方法
CA3084632A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
CN110317832B (zh) 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) * 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
CN108866013B (zh) * 2018-08-06 2021-03-23 武汉赛科成科技有限公司 一种大规模生产慢病毒的方法
EP3854879A4 (en) * 2018-09-20 2022-06-22 National University Corporation Tokyo Medical and Dental University METHOD OF INCREASING THE PRODUCTION OF LENTIVIRUS VECTORS
CN109401969B (zh) * 2018-12-13 2024-02-02 珠海西格膜生物技术有限公司 一种细胞工厂的管道连接系统及其使用方法
JP7333930B2 (ja) * 2019-01-07 2023-08-28 独立行政法人国立高等専門学校機構 ミミズ細胞の保存方法及びミミズ培養細胞の形質転換方法
JP2022551219A (ja) 2019-08-23 2022-12-08 ロンザ ウォーカーズヴィル，インコーポレーテッド レンチウイルスベクターの製造方法および構築物
CN113122501B (zh) * 2019-12-30 2023-06-16 重庆精准生物技术有限公司 适合大规模临床级病毒载体制备的培养基及其应用
JP2023526348A (ja) * 2020-05-15 2023-06-21 アイヴェックスソル インコーポレイテッド 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法
US20230220417A1 (en) * 2020-05-26 2023-07-13 Expression Therapeutics, Llc Lentiviral System
KR20230126214A (ko) * 2020-12-29 2023-08-29 지앙수 젠스크립트 프로바이오 바이오테크 컴퍼니 리미티드 고분산성 hek293t 세포주 및 이의 스크리닝 방법
GB202100688D0 (en) * 2021-01-19 2021-03-03 Autolus Ltd Process
US20240425880A1 (en) * 2021-10-12 2024-12-26 Jiangsu Genscript Probio Biotech Co., Ltd. Hek293 cell line adapted to serum-free suspension culture and use thereof
CA3231011A1 (en) * 2021-10-19 2023-04-27 Amgen Inc. Composition and methods for recombinant lentiviral production
EP4508198A1 (en) * 2022-04-11 2025-02-19 Adverum Biotechnologies, Inc. Optimization of hek293 suspension platform for improved raav titers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US6210922B1 (en) 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
AU2002348151A1 (en) 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
EP2307551B1 (en) 2008-06-18 2016-12-14 Oxford BioMedica (UK) Limited Purification of retroviral vectors
US20110008894A1 (en) 2009-07-07 2011-01-13 Cayla Lyophilized plasmid/dna transfection reagent carrier complex
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
WO2011097447A2 (en) * 2010-02-04 2011-08-11 Neurologix, Inc. Production of recombinant virus
CA2823639A1 (en) 2011-01-05 2012-07-12 Expression Therapeutics, Llc High yield suspension cell line, system, and method for making same
EP2782997B1 (en) 2011-11-24 2018-01-10 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ansorge et al. "Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures", JOURNAL OF GENE MEDICINE, 2009, vol. 11, pages 868 - 876 *
GASMI M ET AL, "REQUIREMENTS FOR EFFICIENT PRODUCTION AND TRANSDUCTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-BASED VECTORS", JOURNAL OF GENERAL VIROLOGY, 1999, vol. 73, pages 1828 - 1834 *
Lesch et al. "Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors."Gene Therapy (2011) 18, 531-538. e-published January 2011. *
Parker et al. European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress October 2011. Pgs. 1-4. *
Segura et al, "Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification", BIOTECHNOLOGY AND BIOENGINEERING, 2007, vol. 98, pages 789 - 799 *
Stewart et al. "Development of inducible EIAV-based lentiviral vector packaging and producer cell lines."Gene Ther. 2009 Jun;16(6):805-14. *

Also Published As

Publication number Publication date
ES2663815T3 (es) 2018-04-17
CN104136605B (zh) 2018-08-14
EP2782997A1 (en) 2014-10-01
CN109097398A (zh) 2018-12-28
EP3327119A1 (en) 2018-05-30
CA2856455C (en) 2022-08-23
SG11201402584RA (en) 2014-06-27
JP2018046828A (ja) 2018-03-29
SI2782997T1 (en) 2018-04-30
DK2782997T3 (en) 2018-04-16
JP6280869B2 (ja) 2018-02-14
PL2782997T3 (pl) 2018-06-29
WO2013076309A1 (en) 2013-05-30
RS57066B1 (sr) 2018-06-29
LT2782997T (lt) 2018-05-25
HRP20180424T1 (hr) 2018-06-29
CA2856455A1 (en) 2013-05-30
JP2014533516A (ja) 2014-12-15
US20220235371A1 (en) 2022-07-28
AU2012342355A1 (en) 2014-07-17
US20190211360A1 (en) 2019-07-11
EP2782997B1 (en) 2018-01-10
BR112014012600A2 (pt) 2017-06-06
CN104136605A (zh) 2014-11-05
SMT201800174T1 (it) 2018-07-17
PT2782997T (pt) 2018-04-09
US20140315294A1 (en) 2014-10-23
CY1120103T1 (el) 2018-12-12
HUE036742T2 (hu) 2018-07-30

Similar Documents

Publication Publication Date Title
US20220235371A1 (en) Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
Merten et al. Production of lentiviral vectors
KR20200056429A (ko) 레트로바이러스 벡터
CA2985828C (en) Bio-production of lentiviral vectors
KR20090121320A (ko) 렌티바이러스 벡터의 제조
JP6212039B2 (ja) 真核細胞の形質導入に有用なウイルスベースのベクター組成物
EP3778880A1 (en) Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells
EP4143327A1 (en) Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity
CA2920191C (en) Methods of improving titer in transfection-based production systems using eukaryotic cells
Wolkowicz et al. Lentiviral vectors for the delivery of DNA into mammalian cells
HK1255189A1 (en) Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
JP2013208107A (ja) レトロウイルスベクターの製造方法
KR20230006553A (ko) 충전층 생물반응기에서의 렌티바이러스 벡터 제조 공정
JP2023507554A (ja) レンチウイルスベクターの一過性産生のための方法および構築物
Hallum Improvements in Lentiviral Vector Design, Production, Purification and Transduction for Increased Biosafety and Gene Delivery Efficiency
Williams-Fegredo Developing strategies to enhance transfection efficiency and mitigate auto-transduction in transient lentiviral vector bioprocessing
EP4118240A1 (en) Replication competent virus assay
Guy Microscale characterisation of a manufacturing route for lentiviral vectors
CN117677706A (zh) 慢病毒载体
HK40042109A (en) Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells
EP3394271A1 (en) Stable integration of sin transfer vectors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired